SciELO - Scientific Electronic Library Online

 
vol.66 issue5The efficacy of a simplified intraoperative adjustable suture for horizontal strabismus surgery: a prospective study of 49 patientsPosterior chamber phakic lens for the correction of hyperopia following radial keratotomy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

Share


Arquivos Brasileiros de Oftalmologia

Print version ISSN 0004-2749On-line version ISSN 1678-2925

Abstract

BALLALAI, Priscilla Luppi et al. Topical use of mitomycin C for the treatment of corneal-conjunctival intraepithelial neoplasia and conjunctival squamous cell carcinoma: preliminary results. Arq. Bras. Oftalmol. [online]. 2003, vol.66, n.5, pp.559-562. ISSN 1678-2925.  https://doi.org/10.1590/S0004-27492003000500003.

PURPOSE: The purpose of this study is to evaluate the safety, efficacy and recurrence after topical use of mitomycin C (MMC) for primary or recurrent corneal-conjunctival intraepithelial neoplasia (CIN) and recurrent squamous cell carcinoma (SCC). METHODS: Two groups of patients were trated. Group 1 patients with primary or recurrent CIN were treated with topical 0.02% MMC, qid for 28 days. Group 2, patients with recurrent SCC, were treated with topical 0.02% MMC, qid for 21 to28 days. RESULTS: Eight patients with CIN and 1with SCC had a total regression of the lesion and all of them had negative control exfoliative cytology for neoplastic cells. One patient with CIN and 2 with SCC had partial regression of the lesions, which were excised surgically, and the pathology was negative for neoplasia. Side effects were transient and subsided after descontinuation of the treatment. There was no recurrence of the lesions on a mean follow-up of 24.9 months. CONCLUSION: The preliminary results of this study suggest that the use of the topical MMC is safe and efficient for the treatment of primary and recurrent CIN and recurrent SCC, although it did not prevent surgery in almost all cases of CEC. There were no recurrences during the follow-up. Further studies with more patients and longer follow-up are necessary to confirm this results.

Keywords : Mitomycin [therapeutic use]; Eye neoplasms [drug therapy]; Conjunctival neoplasms [drug therapy]; Carcinoma, squamous cell [drug therapy].

        · abstract in Portuguese     · text in Portuguese     · Portuguese ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License